Life settlement premium financing 2026: levered IRR math and the anti-STOLI distinction.
Most life settlement content treats premium funding as a cash flow line item. This article walks accredited investors through premium financing as a leverage structure — levered versus unlevered IRR math, lender terms, and the critical distinction from anti-STOLI flagged origination.
Life settlement premium financing is a leverage structure where a lender funds ongoing premium payments on an already-acquired policy in exchange for a security interest in the policy or its proceeds. When properly structured post-acquisition, it can enhance investor IRR by 200-400 basis points on a $500K face value policy — but it introduces leverage risk, lender cost-of-funds drag, and operational complexity that must be carefully analyzed. The structure is distinct from STOLI (Stranger-Originated Life Insurance) origination financing, which is void ab initio under modern state precedent including Sun Life v. Wells Fargo (NJ 2019). Typical lender structures include non-recourse loans at 60-75% LTV against projected death benefit, interest rates of SOFR + 300-500 basis points, and default triggers tied to LE estimate breach. Invest in life settlements through HYV in the institutional segment where premium financing arrangements receive specialized diligence review.
This article addresses premium financing as a POST-ACQUISITION leverage structure — funding ongoing premium payments on policies acquired through legitimate secondary market transactions. This is structurally distinct from STOLI (Stranger-Originated Life Insurance) origination financing, where a stranger funds the original policy purchase with intent of subsequent assignment. STOLI arrangements are void ab initio under modern state precedent including Sun Life Assurance Co. of Canada v. Wells Fargo Bank, N.A. (NJ 2019) and PHL Variable Insurance Co. v. Price Dawe (Delaware). Anti-STOLI provisions in 29 states prohibit such arrangements. Premium financing on a legitimately acquired secondary market policy does NOT violate anti-STOLI rules; premium financing at original policy issuance with stranger intent DOES. This distinction governs the entire framework below.
Premium financing in the life settlement market sits at an analytical intersection few investor-side articles address. On one hand, it is a powerful leverage structure that institutional investors regularly use to enhance returns on individual direct-ownership positions or portfolio allocations. On the other hand, it carries a legacy of regulatory concern — premium financing was historically associated with STOLI arrangements that modern state law now treats as void. After more than two decades structuring post-acquisition financing arrangements alongside accredited investors and family offices, the framework below explains where the legitimate structure operates, how the levered IRR math works, and what diligence accredited investors should expect from any platform presenting premium-financed opportunities.
What premium financing is — and what it is not
Premium financing in the context of life settlements is a post-acquisition lending arrangement. An accredited investor or institutional buyer has acquired a life settlement policy through a legitimate secondary market transaction. The policy is in-force, the investor is the new owner, and ongoing premium payments are required through the projected life expectancy. Rather than fund those premiums from the investor's own capital, a specialized lender funds them — taking a security interest in the policy or its proceeds as collateral.
Three structural elements distinguish premium financing from other leverage structures. First, the underlying asset is the life insurance policy. The lender's collateral is either the policy itself (with rights to step into the investor's position upon default) or a security interest in the death benefit proceeds. Second, the cash flows are asymmetric. The lender funds premiums regularly throughout the holding period; the lender is repaid in a single lump sum at maturity from the death benefit proceeds. Third, the loan duration matches the policy's LE estimate. Unlike traditional commercial loans with fixed maturities, premium financing loans typically mature at the insured's death — meaning duration is uncertain.
The structure exists because investors who allocate to life settlements often face a cash flow timing mismatch. Capital is deployed at acquisition; death benefit is received years later at maturity; but premium payments are required throughout. Premium financing converts the recurring premium obligation into a lender-funded line, freeing the investor's capital for other deployment. For institutional investors managing portfolio liquidity, this is operationally and economically meaningful.
The anti-STOLI distinction in detail
Understanding what premium financing is requires understanding what it is not. STOLI — Stranger-Originated Life Insurance — refers to arrangements where a stranger to the insured funds the original policy purchase with the intent of immediate or shortly subsequent assignment to the stranger. The wagering concern that Justice Holmes preserved in Grigsby v. Russell (1911) operates at the origination stage: insurable interest must be present at policy issuance.
STOLI arrangements typically involve premium financing at the origination moment — the stranger funds the original premium payments, often through a non-recourse loan to the insured, with the policy intended to be assigned to the stranger after the contestability period. This structure is void ab initio under modern state precedent including Sun Life Assurance Co. of Canada v. Wells Fargo Bank, N.A. (NJ 2019) and PHL Variable Insurance Co. v. Price Dawe (Delaware). Twenty-nine U.S. states have enacted explicit anti-STOLI provisions prohibiting such arrangements at origination.
The distinction matters operationally. Post-acquisition premium financing on a legitimately acquired secondary market policy is structurally different. The original policy was issued with proper insurable interest at the time of origination. The investor acquired the policy through a state-licensed transaction that complied with anti-STOLI provisions. The post-acquisition financing is a financial structure layered on a clean foundational policy — not a wagering arrangement disguised as insurance at the origination moment.
For accredited investors, the practical implication is that premium financing arrangements must be verified to be post-acquisition rather than incorporated into the original policy structure. Any presentation that combines premium financing with policy origination in close temporal proximity warrants extraordinary scrutiny — and in most cases, should be avoided regardless of how favorable the projected returns appear.
Levered vs unlevered IRR — the worked example
The economic case for premium financing rests on the levered IRR enhancement relative to the unlevered base case. The comparison below uses representative parameters: a $500,000 face value policy acquired for $156,800 (the same example used in our pricing math article), 60-month LE, $30,000 annual premium, and a premium financing loan at SOFR + 400bp covering 100% of premiums through projected maturity.
Unlevered vs levered IRR
Investor funds all premiums
Lender funds premiums at 9.5%
The levered scenario produces approximately 350 basis points of IRR enhancement over the unlevered base case — meaningful but not unlimited. Several observations about the math deserve emphasis. The IRR enhancement is bounded by the spread between policy economic yield and lender cost-of-funds. The unlevered IRR of approximately 14% reflects the policy's intrinsic return; the lender's all-in rate of approximately 9.5% reflects the cost of borrowed capital. The difference — roughly 450 basis points — is the potential enhancement, of which the levered IRR captures a substantial portion.
The investor's capital efficiency improves materially. In the unlevered case, the investor deploys $306,800 to capture $193,200 of gain. In the levered case, the investor deploys $156,800 to capture $168,200 of gain. Same policy, similar absolute returns, half the capital outlay. For an investor managing a portfolio with constrained capital, leverage releases capacity to allocate to additional positions.
The IRR enhancement depends on LE outcome. If the insured outlives the LE estimate, premium payments extend beyond projection, lender interest compounds longer, and the levered IRR compresses faster than the unlevered IRR. Risk amplification under leverage is the structural cost of the IRR enhancement — covered in the dedicated section below.
Typical lender structures and term sheets
Premium financing lenders in the life settlement market typically offer standardized structures across a few key dimensions. Understanding each dimension allows accredited investors to compare term sheets across lenders and evaluate fit with their specific allocation strategy.
The five components together define the lender's risk profile and the investor's return enhancement. For accredited investors evaluating premium financing arrangements presented through institutional platforms, term sheet comparison across multiple lenders is essential — modest spread differences across lenders can compound into materially different levered IRR over a 60-month holding period.
Browse vetted life settlement opportunities
HYV opportunities involving premium financing arrangements are presented with full structure documentation — lender terms, LTV cap, interest rate spread, default triggers, and anti-STOLI compliance verification — for accredited investor review.
Browse the platformRisk amplification under leverage
Premium financing enhances IRR but also amplifies risk. Accredited investors and their advisors should understand the specific risk mechanisms that operate differently under leverage than in the unlevered base case.
- Longevity risk amplification. If the insured significantly outlives the LE estimate, the unlevered investor experiences compressed IRR through extended premium payments and delayed death benefit. The levered investor experiences the same compression PLUS accumulating loan interest, accelerating the IRR erosion. Each additional month of life extension carries higher cost under leverage.
- LTV cap breach scenarios. If updated LE estimates extend the projected payout date, the loan balance plus accrued interest can exceed the LTV cap — triggering refinancing requirements, additional collateral posting, or in extreme cases, loan acceleration. Investors should model multiple LE extension scenarios before accepting leverage.
- Capital efficiency vs concentration risk. Leverage releases capital for additional positions, which improves diversification potential. But if multiple leveraged positions experience LE extension simultaneously, the combined refinancing pressure can create a concentrated liquidity event. Portfolio-level leverage management is essential.
- Lender dependency risk. Premium funding depends on the lender continuing to honor the funding commitment. Lender credit events, regulatory changes affecting specialty lenders, or borrowing facility termination can disrupt premium payment continuity — risking policy lapse during the holding period.
- Refinancing risk in floating-rate structures. SOFR + spread structures expose the investor to rising rate scenarios. If short-term rates rise materially during the holding period, levered IRR compresses faster than projected. Fixed-rate structures eliminate this risk at the cost of typically higher initial spreads.
For institutional investors who invest in life settlement policies through HYV, opportunities involving premium financing receive specialized diligence applied to all five risk dimensions plus the standard 30-item pre-acquisition checklist. Term sheet review, LTV scenario modeling, anti-STOLI compliance verification, and post-acquisition timing confirmation are all part of the institutional buy-side workflow for leveraged structures.
Typical IRR enhancement that post-acquisition premium financing provides over unlevered allocation on a $500K face value policy at standard institutional lender terms. Risk amplification scales proportionally — meaning the enhanced return comes with proportionally larger downside if LE outcomes deviate materially from projection. The SEC Investor Bulletin on Life Settlements documents the institutional structure context.
Invest in life settlements with specialized leverage diligence
HYV opportunities involving premium financing receive full structure documentation review — lender terms, LTV cap scenarios, anti-STOLI compliance verification — before reaching the accredited investor desk.
Premium financing in the U.S. life settlement market operates as a post-acquisition leverage structure where a specialized lender funds ongoing premium payments on an already-acquired policy in exchange for a security interest in the policy or its proceeds. Typical lender structures include non-recourse loans at 60-75% loan-to-value against projected death benefit, floating-rate pricing at SOFR + 300-500 basis points, security interests in death benefit proceeds rather than policy ownership during the loan term, and default triggers tied to LE estimate breach and premium deficiency events. The structure is distinct from STOLI (Stranger-Originated Life Insurance) origination financing, which is void ab initio under modern state precedent including Sun Life Assurance Co. of Canada v. Wells Fargo Bank, N.A. (NJ 2019), PHL Variable Insurance Co. v. Price Dawe 2006 Insurance Trust (Delaware), and anti-STOLI provisions in 29 U.S. states.
The legitimate post-acquisition use of premium financing involves policies already in the secondary market that comply with state-level licensing, anti-STOLI provisions, waiting period requirements (typically 2-5 years from policy issuance to first assignment), and consumer disclosures under NCOIL Life Settlement Model Act and NAIC Viatical Settlements Model Act frameworks. The FINRA Investor Insights on Life Settlements and the NAIC Viatical Settlements Model Act framework provide regulatory context. Federal investor accreditation under SEC Rule 501 of Regulation D applies to all leveraged and unleveraged life settlement direct-ownership investments.
The economic case for premium financing rests on the spread between the policy's intrinsic economic yield (typically 12-16% IRR for direct-ownership institutional buyers) and the lender's all-in cost-of-funds (typically SOFR + 300-500bp = 8-10% in current rate environment). The levered IRR enhancement of 200-400 basis points over the unlevered base case reflects this spread capture, net of lender interest costs. Industry data and structure benchmarks are published by the Life Insurance Settlement Association (LISA) and complementary research. The U.S. life settlement market transacts approximately $4.6 billion annually with an addressable supply estimated by Conning Research at $224 billion, supporting a growing institutional infrastructure including specialized premium financing lenders.
Invest in life settlements with leverage transparency
HYV opportunities involving post-acquisition premium financing arrive with full structure documentation — anti-STOLI compliance, lender terms, levered IRR scenarios under multiple LE outcomes — for accredited investor and advisor review.
Frequently asked questions
What is life settlement premium financing?
Life settlement premium financing is a post-acquisition leverage structure where a specialized lender funds ongoing premium payments on an already-acquired life settlement policy. The investor has acquired the policy through a legitimate secondary market transaction; the lender provides capital for the recurring premium obligations, taking a security interest in the policy or its proceeds as collateral. The structure converts the investor's recurring premium cash outflow into a lender-funded line, freeing investor capital for other deployment while typically enhancing IRR by 200-400 basis points relative to the unlevered base case. The structure is distinct from STOLI origination financing, which is void ab initio under modern state precedent.
How does premium financing differ from STOLI?
The critical distinction is timing and intent. STOLI (Stranger-Originated Life Insurance) arrangements involve premium financing at the original policy purchase moment, where a stranger to the insured funds the initial premiums with the intent of subsequent assignment to the stranger. This violates insurable interest requirements at origination and is void ab initio under Sun Life v. Wells Fargo (NJ 2019), PHL v. Price Dawe (DE), and anti-STOLI provisions in 29 states. Post-acquisition premium financing on a legitimately acquired secondary market policy is structurally different — the original policy was issued with proper insurable interest, the investor acquired it through state-compliant transaction, and the financing is layered on a clean foundational policy. Investors should verify any premium financing arrangement is genuinely post-acquisition rather than incorporated into original policy structure.
How much can premium financing enhance my IRR?
Typical IRR enhancement from premium financing on institutional terms is 200-400 basis points over the unlevered base case. For a $500K face value policy with 60-month LE at standard 14% unlevered IRR, premium financing at SOFR + 400bp can enhance levered IRR to approximately 17-18%. The enhancement reflects the spread between the policy's intrinsic economic yield and the lender's all-in cost-of-funds, captured by the investor as levered return. The enhancement is bounded by this spread and varies materially by lender terms, LE outcome, and rate environment. Higher LTV ratios produce larger enhancements at proportionally higher risk amplification.
What are the risks of premium financing?
Five primary risks operate differently under leverage than in the unlevered base case: (1) longevity risk amplification — life extension beyond LE estimate compresses IRR faster under leverage due to accumulating loan interest; (2) LTV cap breach scenarios — extended payout dates can cause loan balance plus interest to exceed cap, triggering refinancing or additional collateral; (3) capital efficiency vs concentration risk — leverage releases capital for additional positions but creates simultaneous LE extension exposure; (4) lender dependency risk — credit events or regulatory changes affecting specialty lenders can disrupt premium funding continuity; (5) refinancing risk in floating-rate structures — rising rate scenarios compress levered IRR faster than projected. Accredited investors should model multiple LE extension scenarios and rate paths before committing to leveraged structures.
What are typical premium financing terms?
Institutional premium financing structures typically involve: 60-75% loan-to-value against projected death benefit; interest rates at SOFR + 300-500 basis points (floating-rate) or fixed-rate alternatives; non-recourse structures with security interest in policy proceeds rather than policy ownership during loan term; default triggers tied to LE estimate breach, premium deficiency, and policy lapse risk; collateral structure where the investor remains policy owner and named beneficiary while the lender holds a security interest. Term sheet variation across lenders can produce materially different levered IRR over a 60-month holding period; institutional investors compare multiple lender proposals before committing.
Is premium financing legal in all states?
Post-acquisition premium financing on legitimately acquired secondary market policies is generally legal across U.S. states, subject to applicable lending regulations and life settlement licensing frameworks. Premium financing at original policy issuance with stranger-origination intent is prohibited or restricted under anti-STOLI provisions in 29 U.S. states, void ab initio under modern state Supreme Court precedent (Sun Life v. Wells Fargo NJ 2019, PHL v. Price Dawe DE), and structurally distinct from the post-acquisition leverage discussed in this article. Specific state-by-state regulatory considerations apply; investors should verify lender compliance with applicable state lending regulations and confirm the underlying policy origination complies with anti-STOLI provisions before accepting any premium-financed structure.
How does premium financing affect tax treatment?
Premium financing has nuanced effects on the investor's tax treatment. Under Revenue Ruling 2009-14, investor basis equals purchase price plus premiums paid; in a premium-financed structure, the question of whether lender-funded premiums add to basis (and whether interest payments are deductible) involves interpretive complexity that varies by structuring vehicle and lender arrangement. Some interpretations treat lender-funded premiums as effectively investor-paid for basis purposes; others require netting against the loan balance. Interest deductibility may be subject to investment interest expense limitations under IRC §163(d). CPAs advising on premium-financed allocations typically coordinate with tax counsel before structuring specific transactions. See our life settlement CPA framework article for the broader tax workflow context.
How does HYV diligence premium financing structures?
High Yield Vault applies specialized diligence to any opportunity involving post-acquisition premium financing. Beyond the standard 30-item pre-acquisition checklist applied to all direct-ownership opportunities, premium-financed structures receive specific additional review: anti-STOLI compliance verification confirming the underlying policy origination was legitimate; lender term sheet review across LTV ratio, interest rate spread, recourse type, and default triggers; LE extension scenario modeling showing levered IRR under multiple longevity outcomes; lender credit assessment including financial strength and operational continuity; collateral structure documentation confirming investor remains policy owner during loan term. Across 21 years of practice and 438 accredited investors served, HYV's premium financing diligence framework reflects institutional-grade standards for leveraged structures.
